tbuckley/cabot-search huggingface dataset:
THU-078 Extra-hepatic organ failure in ACLF patients is associated with poor survival and limited curative therapy-results from AARC cohort
Authors: Ashok Kumar Choudhury, Vinod Arora, Mohd. Rela, Dinesh Jothimani, Mamun Al-Mahtab, Harshad Devarbhavi, CE Eapen, Ashish Goel, Cesar Yaghi, Qin Ning, Tao Chen, Zhongping Duan, Saeed Sadiq Hamid, Wasim Jafri, Akash Shukla, Soek-Siam Tan, Dong Joon Kim, Anoop Saraya, Jinhua Hu, Ajit Sood, Omesh Goyal, Manoj Sahoo, Guan-Huei Lee, Sombat Treeprasertsuk, Kessarin Thanapirom, Ameet Mandot, Samir Shah, Laurentius A. Lesmana, Hasmik Ghazinyan, Mohan Prasad V G, A. Kadir Dokmeci, Jose Sollano, Zaigham Abbas, Ananta Shrestha, George Lau, Diana Payawal, Gamal Shiha, Ajay Kumar Duseja, Sunil Taneja, Nagaraja Rao Padaki, Anand Kulkarni, Md. Fazal Karim, Radha Krishan Dhiman, Ajay Mishra, Shahinul Alam, Osamu Yokosuka, Dr. Debashis Chowdhury, Chandan Kedarisetty, Dr Sanjiv Saigal, Anil Arora, Ashish Kumar, Ghulam Nabi Yattoo, Abraham Koshy, Ajay Kumar, Mohammed Elbasiony, Pravin Rathi, Sudhir Maharshi, V.M. Dayal, Ashish Kumar Jha, Kemal Fariz Kalista, Rino Gani, Man-Fung Yuen, Virendra Singh, Ayaskant Singh, Sargsyan Violeta, Chien-Hao Huang, Saurabh Mukewar, Shaojie Xin, Ruveena Bhavani, Charles Panackel, Sunil Dadhich, Sanjeev Sachdeva, Ajay Kumar, Sanatan Behera, Prabir Maji, Lubna Kamani, Hemamala Venugopal Saithanyamurthi, Dr. Joy Varghese, Pathik Parikh, P Javed, Neeraj Saraf, Narendra S. Choudhary, Akash Roy, Mahesh Goenka, Chetan Kalal, Krishnadas Devadas, Gupse Adali, Janaka De Silva H, Masao Omata, Manoj Sharma, Shiv Kumar Sarin
Journal: Journal of Hepatology (2024)
LBP-039 Oral alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast in primary sclerosing cholangitis: updated 12-week interim safety and efficacy analysis of the INTEGRIS-PSC phase 2a trial
Authors: Michael Trauner, Kris V. Kowdley, Gideon M. Hirschfield, Eric Lefebvre, Martin Decaris, Johanna Schaub, Annie Clark, Mandy Lin, Mahru An, Aarthi Balasubramanyam, Chris N. Barnes, Richard Pencek, Douglas Thorburn, Aldo J. Montano-Loza, Christopher L. Bowlus, Christoph Schramm, Cynthia Levy, Palak J. Trivedi
Journal: Journal of Hepatology (2024)
LBP-005 Efficacy, safety, tolerability, and immunogenicity of JNJ-0535 following a reduction of viral antigen levels through administration of siRNA JNJ-3989 in patients with chronic HBeAg negative hepatitis B-interim data of the OSPREY study
Authors: Stefan Bourgeois, Maria Buti, Edward J. Gane, Kosh Agarwal, Ewa Janczewska, Yao-Chun (Holden) Hsu, Maurizia Brunetto, Pietro Lampertico, Joaquin Cabezas, Gloria Kim, Leen Slaets, Adam Bakala, Joris Vandenbossche, Simon Verheijden, Bart Fevery, An De Creus, Michael Biermer, Dessislava Dimitrova
Journal: Journal of Hepatology (2024)
LBP-011 Streamlined serodiagnosis of hepatitis delta: a novel lateral flow assay kit for on-site rapid diagnostics
Authors: Arghun Dashdorj, Nomin Ariungerel, Sunguck Han, Gichan Choi, Su Ah Kim, Tae-Hoon Kim, Kyongman An, Minsup Chung, Odgerel Oidosambuu, Byambasuren Ochirsum, Purevjargal Bat-Ulzii, Enkhnomin Ochirbat, Sanjaasuren Enkhtaivan, Saruul Enkhjargal, Naranbaatar Dashdorj, Naranjargal Dashdorj, Nam Joon Choi
Journal: Journal of Hepatology (2024)
FRI-113 Diagnostic scoring system for diagnosis of covert hepatic encephalopathy in child-pugh class a cirrhosis patients
Authors: Masanori Fukushima, Yasuhiko Nakao, Ryu Sasaki, Masafumi Haraguchi, Satoshi Miuma, Hisamitsu Miyaaki, Kazuhiko Nakao
Journal: Journal of Hepatology (2024)
OS-118 Week 48 results from the phase 2b ENLIVEN extension study investigating pegozafermin for the treatment of metabolic dysfunction-associated steatohepatitis with fibrosis
Authors: Rohit Loomba, Manal F. Abdelmalek, Kris V. Kowdley, Naim Alkhouri, Stephen A. Harrison, Jörn M Schattenberg, Mildred D. Gottwald, Shibao Feng, Germaine D. Agollah, Cynthia L. Hartsfield, Hank Mansbach, Maya Margalit, Arun J Sanyal
Journal: Journal of Hepatology (2024)
FRI-069 Rifaximin monotherapy has significantly reduced the risk of overt hepatic encephalopathy recurrence versus lactulose monotherapy in patients with cirrhosis and a history of previous episode (s): a post hoc analysis of randomized trials
Authors: Jasmohan Bajaj, Robert Rahimi, Christopher Allen, Zeev Heimanson, Robert Israel, Kris V. Kowdley
Journal: Journal of Hepatology (2024)
WED-120 Albumin infusion in decompensated cirrhotic patients with ascites induced decreasing serum active form of vitamin D, 1, 25 dihydroxy vitamin D, an opposite effect on promoting systemic inflammatory cytokines reduction
Authors: Thitaporn Roongrawee, Sirinporn Suksawatamnuay, Nunthiya Srisoonthorn, Nipaporn Siripon, Panarat Thaimai, Prooksa Ananchuensook, Supachaya Sriphoosanaphan, Kessarin Thanapirom, Piyawat Komolmit
Journal: Journal of Hepatology (2024)
FRI-056-YI Clinical impact of acute kidney disease in patients with decompensated cirrhosis: insights from a prospective observational study on renal dysfunction
Authors: Alberto Calleri, Marco Tizzani, Francesco Frigo, Elisa Bertoldi, Daniela Campion, Gian Paolo Caviglia, Antonio Ottobrelli, Alfredo Marzano, Giorgio Maria Saracco, Carlo Alessandria
Journal: Journal of Hepatology (2024)
WED-081 Carvedilol decreases hepatic vascular resistance in cirrhosis by deactivating hepatic stellate cells (HSC) and improving liver sinusoidal endothelial cells (LSEC) dysfunction, resulting in decreased liver fibrosis and improved nitric oxide release
Authors: Yeldos Nulan, Eric Felli, Cong Wang, Sonia Emilia Selicean, Annalisa Berzigotti, Jordi Gracia-Sancho, Jaime Bosch
Journal: Journal of Hepatology (2024)
LBP-022 Preclinical safety data for PBGENE-HBV gene editing program supports advancement to clinical trials as a potentially curative treatment for chronic hepatitis B
Authors: Emily Harrison, Keely Dulmage, Katie Evans, Haley Grimason, Nicole Heard, Adepeju Aseyiga, Whitney Lewis, Ben Morris, Arpan Mukherjee, Traci Reddick, Andrew Van Cott, Dan Nazarenko, Ying Tam, Sean Semple, Neil Leatherbury, Janel Lape, Jeff Smith, Cassandra Gorsuch
Journal: Journal of Hepatology (2024)
GS-004 Prognostic significance of a change in liver stiffness measurement by vibration-controlled transient elastography-a multicenter cohort study of 10, 920 patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
Authors: Terry Cheuk-Fung Yip, Hye Won Lee, Huapeng Lin, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jerome Boursier, José Luis Calleja Panero, George Boon Bee Goh, Wah-Kheong Chan, Rocio Gallego-Durán, Arun J Sanyal, Victor de Lédinghen, Philip N. Newsome, Jiangao Fan, Laurent Castera, Michelle Lai, Stephen A. Harrison, Céline Fournier-Poizat, Grace Lai-Hung Wong, Grazia Pennisi, Angelo Armandi, Atsushi Nakajima, Wen-Yue Liu, Ying Shang, Marc de Saint-Loup, Elba Llop Herrera, Kevin Kim Jun Teh, Carmen Lara-Romero, Amon Asgharpour, Sara Mahgoub, Chan Mandy, Clémence M Canivet, Manuel Romero-Gómez, Seung Up Kim, Vincent Wai-Sun Wong
Journal: Journal of Hepatology (2024)
OS-015 Time to complete biochemical response and disease progression in autoimmune hepatitis
Authors: Martine A.M.C. Baven-Pronk, Charlotte Slooter, Ana Lleo, Francesca Colapietro, Marco Lenzi, Paolo Muratori, Nanda Kerkar, George Dalekos, Kalliopi Zachou, Maria Isabel Lucena, Mercedes Robles-Díaz, Daniel E. Di Zeo-Sánchez, Raul J. Andrade, Aldo J Montano-Loza, Ellina Lytvyak, Birgitte Lissenberg-Witte, Patrick Maisonneuve, Gerd Bouma, Guilherme Macedo, Rodrigo Liberal, Maarten Tushuizen, Joost PH Drenth, Ynto de Boer, Bart van Hoek
Journal: Journal of Hepatology (2024)
GS-011 Denifanstat, a fatty acid synthase (FASN) inhibitor, shows significant fibrosis improvement and MASH resolution in FASCINATE-2, a Ph2b 52 week international, randomized, double blind, placebo-controlled trial in patients with F2 or F3 fibrosis
Authors: Rohit Loomba, Eduardo Martins, Katharine Grimmer, Wen-Wei Tsai, Marie O' Farrell, William McCulloch, George Kemble, Pierre Bedossa, Jose Cobiella, Eric Lawitz, Madhavi Rudraraju, Stephen A. Harrison
Journal: Journal of Hepatology (2024)
Single molecule array measures of LRRK2 kinase activity in serum link Parkinson’s disease severity to peripheral inflammation
Authors: Yuan Yuan, Huizhong Li, Kashyap Sreeram, Tuyana Malankhanova, Ravindra Boddu, Samuel Strader, Allison Chang, Nicole Bryant, Talene A. Yacoubian, David G. Standaert, Madalynn Erb, Darren J. Moore, Laurie H. Sanders, Michael W. Lutz, Dmitry Velmeshev, Andrew B. West
Journal: Molecular Neurodegeneration (2024)

Abstract Background LRRK2-targeting therapeutics that inhibit LRRK2 kinase activity have advanced to clinical trials in idiopathic Parkinson’s disease (iPD). LRRK2 phosphorylates Rab10 on endolysosomes in phagocytic cells to promote some types of immunological responses. The identification of factors that regulate LRRK2-mediated Rab10 phosphorylation in iPD, and whether phosphorylated-Rab10 levels change in different disease states, or with disease progression, may provide insights into the role of Rab10 phosphorylation in iPD and help guide therapeutic strategies targeting this pathway. Methods Capitalizing on past work demonstrating LRRK2 and phosphorylated-Rab10 interact on vesicles that can shed into biofluids, we developed and validated a high-throughput single-molecule array assay to measure extracellular pT73-Rab10. Ratios of pT73-Rab10 to total Rab10 measured in biobanked serum samples were compared between informative groups of transgenic mice, rats, and a deeply phenotyped cohort of iPD cases and controls. Multivariable and weighted correlation network analyses were used to identify genetic, transcriptomic, clinical, and demographic variables that predict the extracellular pT73-Rab10 to total Rab10 ratio. Results pT73-Rab10 is absent in serum from Lrrk2 knockout mice but elevated by LRRK2 and VPS35 mutations, as well as SNCA expression. Bone-marrow transplantation experiments in mice show that serum pT73-Rab10 levels derive primarily from circulating immune cells. The extracellular ratio of pT73-Rab10 to total Rab10 is dynamic, increasing with inflammation and rapidly decreasing with LRRK2 kinase inhibition. The ratio of pT73-Rab10 to total Rab10 is elevated in iPD patients with greater motor dysfunction, irrespective of disease duration, age, sex, or the usage of PD-related or anti-inflammatory medications. pT73-Rab10 to total Rab10 ratios are associated with neutrophil degranulation, antigenic responses, and suppressed platelet activation. Conclusions The extracellular serum ratio of pT73-Rab10 to total Rab10 is a novel pharmacodynamic biomarker for LRRK2-linked innate immune activation associated with disease severity in iPD. We propose that those iPD patients with higher serum pT73-Rab10 levels may benefit from LRRK2-targeting therapeutics that mitigate associated deleterious immunological responses.
Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised DACAB trial
Authors: Yunpeng Zhu, Wei Zhang, Arnaldo Dimagli, Lin Han, Zhaoyun Cheng, Ju Mei, Xin Chen, Xiaowei Wang, Yanzai Zhou, Qing Xue, Junlong Hu, Min Tang, Rui Wang, Yuanyuan Song, Lei Kang, Bjorn Redfors, Mario Gaudino, Qiang Zhao
Journal: BMJ (2024)

To assess the effect of different antiplatelet strategies on clinical outcomes after coronary artery bypass grafting. Five year follow-up of randomised Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Grafting (DACAB) trial. Six tertiary hospitals in China; enrolment between July 2014 and November 2015; completion of five year follow-up from August 2019 to June 2021. 500 patients aged 18-80 years (including 91 (18.2%) women) who had elective coronary artery bypass grafting surgery and completed the DACAB trial. Patients were randomised 1:1:1 to ticagrelor 90 mg twice daily plus aspirin 100 mg once daily (dual antiplatelet therapy; n=168), ticagrelor monotherapy 90 mg twice daily (n=166), or aspirin monotherapy 100 mg once daily (n=166) for one year after surgery. After the first year, antiplatelet therapy was prescribed according to standard of care by treating physicians. The primary outcome was major adverse cardiovascular events (a composite of all cause death, myocardial infarction, stroke, and coronary revascularisation), analysed using the intention-to-treat principle. Time-to-event analysis was used to compare the risk between treatment groups. Multiple post hoc sensitivity analyses examined the robustness of the findings. Follow-up at five years for major adverse cardiovascular events was completed for 477 (95.4%) of 500 patients; 148 patients had major adverse cardiovascular events, including 39 in the dual antiplatelet therapy group, 54 in the ticagrelor monotherapy group, and 55 in the aspirin monotherapy group. Risk of major adverse cardiovascular events at five years was significantly lower with dual antiplatelet therapy versus aspirin monotherapy (22.6% v 29.9%; hazard ratio 0.65, 95% confidence interval 0.43 to 0.99; P=0.04) and versus ticagrelor monotherapy (22.6% v 32.9%; 0.66, 0.44 to 1.00; P=0.05). Results were consistent in all sensitivity analyses. Treatment with ticagrelor dual antiplatelet therapy for one year after surgery reduced the risk of major adverse cardiovascular events at five years after coronary artery bypass grafting compared with aspirin monotherapy or ticagrelor monotherapy. NCT03987373ClinicalTrials.gov NCT03987373.
Computationally derived transition points across phases of clinical care
Authors: Aidan Gilson, David Chartash, R. Andrew Taylor, Laura C. Hart
Journal: npj Digital Medicine (2024)

Abstract The objective of this study is to use statistical techniques for the identification of transition points along the life course, aiming to identify fundamental changes in patient multimorbidity burden across phases of clinical care. This retrospective cohort analysis utilized 5.2 million patient encounters from 2013 to 2022, collected from a large academic institution and its affiliated hospitals. Structured information was systematically gathered for each encounter and three methodologies - clustering analysis, False Nearest Neighbor, and transitivity analysis - were employed to pinpoint transitions in patients’ clinical phase. Clustering analysis identified transition points at age 2, 17, 41, and 66, FNN at 4.27, 5.83, 5.85, 14.12, 20.62, 24.30, 25.10, 29.08, 33.12, 35.7, 38.69, 55.66, 70.03, and transitivity analysis at 7.27, 23.58, 29.04, 35.00, 61.29, 67.03, 77.11. Clustering analysis identified transition points that align with the current clinical gestalt of pediatric, adult, and geriatric phases of care. Notably, over half of the transition points identified by FNN and transitivity analysis were between ages 20 and 40, a population that is traditionally considered to be clinically homogeneous. Few transition points were identified between ages 3 and 17. Despite large social and developmental transition at those ages, the burden of multimorbidities may be consistent across the age range. Transition points derived through unsupervised machine learning approaches identify changes in the clinical phase that align with true differences in underlying multimorbidity burden. These transitions may be different from conventional pediatric and geriatric phases, which are often influenced by policy rather than clinical changes.
AI and immunology
Authors: Ronald N. Germain, Eliezer M. Van Allen, Gosia Trynka, John S. Tsang, Dominic Grün, Ashley L. Kiemen, Yigong Shi, Aimee Pugh Bernard, Garry P. Nolan
Journal: Immunity (2024)

AI is rapidly becoming part of many aspects of daily life, with an impact that reaches all fields of research. We asked investigators to share their thoughts on how AI is changing immunology research, what is necessary to move forward, the potential and the pitfalls, and what will remain unchanged as the field journeys into a new era.
Spatial transcriptomics analysis identifies a tumor-promoting function of the meningeal stroma in melanoma leptomeningeal disease
Authors: Hasan Alhaddad, Oscar E. Ospina, Mariam Lotfy Khaled, Yuan Ren, Ethan Vallebuona, Mohammad Baraa Boozo, Peter A. Forsyth, Yolanda Pina, Robert Macaulay, Vincent Law, Kenneth Y. Tsai, W. Douglas Cress, Brooke Fridley, Inna Smalley
Journal: Cell Reports Medicine (2024)

Leptomeningeal disease (LMD) remains a rapidly lethal complication for late-stage melanoma patients. Here, we characterize the tumor microenvironment of LMD and patient-matched extra-cranial metastases using spatial transcriptomics in a small number of clinical specimens (nine tissues from two patients) with extensive in vitro and in vivo validation. The spatial landscape of melanoma LMD is characterized by a lack of immune infiltration and instead exhibits a higher level of stromal involvement. The tumor-stroma interactions at the leptomeninges activate tumor-promoting signaling, mediated through upregulation of SERPINA3. The meningeal stroma is required for melanoma cells to survive in the cerebrospinal fluid (CSF) and promotes MAPK inhibitor resistance. Knocking down SERPINA3 or inhibiting the downstream IGR1R/PI3K/AKT axis results in tumor cell death and re-sensitization to MAPK-targeting therapy. Our data provide a spatial atlas of melanoma LMD, identify the tumor-promoting role of meningeal stroma, and demonstrate a mechanism for overcoming microenvironment-mediated drug resistance in LMD.
Performance of newer myeloma staging systems in a contemporary, large patient cohort
Authors: Ghulam Rehman Mohyuddin, Samuel M. Rubinstein, Shaji Kumar, S. Vincent Rajkumar, Rafael Fonseca, Nadine H. Abdallah, Gregory S. Calip, Xiaoyan Wang, Christina M. Parrinello, Douglas Sborov
Journal: Blood Cancer Journal (2024)
FoldPAthreader: predicting protein folding pathway using a novel folding force field model derived from known protein universe
Authors: Kailong Zhao, Pengxin Zhao, Suhui Wang, Yuhao Xia, Guijun Zhang
Journal: Genome biology (2024)

Abstract Protein folding has become a tractable problem with the significant advances in deep learning-driven protein structure prediction. Here we propose FoldPAthreader, a protein folding pathway prediction method that uses a novel folding force field model by exploring the intrinsic relationship between protein evolution and folding from the known protein universe. Further, the folding force field is used to guide Monte Carlo conformational sampling, driving the protein chain fold into its native state by exploring potential intermediates. On 30 example targets, FoldPAthreader successfully predicts 70% of the proteins whose folding pathway is consistent with biological experimental data.
Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations
Authors: Syuzo Kaneko, Ken Takasawa, Ken Asada, Kouya Shiraishi, Noriko Ikawa, Hidenori Machino, Norio Shinkai, Maiko Matsuda, Mari Masuda, Shungo Adachi, Satoshi Takahashi, Kazuma Kobayashi, Nobuji Kouno, Amina Bolatkan, Masaaki Komatsu, Masayoshi Yamada, Mototaka Miyake, Hirokazu Watanabe, Akiko Tateishi, Takaaki Mizuno, Yu Okubo, Masami Mukai, Tatsuya Yoshida, Yukihiro Yoshida, Hidehito Horinouchi, Shun-Ichi Watanabe, Yuichiro Ohe, Yasushi Yatabe, Vassiliki Saloura, Takashi Kohno, Ryuji Hamamoto
Journal: Molecular Cancer (2024)

Abstract Background In an extensive genomic analysis of lung adenocarcinomas (LUADs), driver mutations have been recognized as potential targets for molecular therapy. However, there remain cases where target genes are not identified. Super-enhancers and structural variants are frequently identified in several hundred loci per case. Despite this, most cancer research has approached the analysis of these data sets separately, without merging and comparing the data, and there are no examples of integrated analysis in LUAD. Methods We performed an integrated analysis of super-enhancers and structural variants in a cohort of 174 LUAD cases that lacked clinically actionable genetic alterations. To achieve this, we conducted both WGS and H3K27Ac ChIP-seq analyses using samples with driver gene mutations and those without, allowing for a comprehensive investigation of the potential roles of super-enhancer in LUAD cases. Results We demonstrate that most genes situated in these overlapped regions were associated with known and previously unknown driver genes and aberrant expression resulting from the formation of super-enhancers accompanied by genomic structural abnormalities. Hi-C and long-read sequencing data further corroborated this insight. When we employed CRISPR-Cas9 to induce structural abnormalities that mimicked cases with outlier ERBB2 gene expression, we observed an elevation in ERBB2 expression. These abnormalities are associated with a higher risk of recurrence after surgery, irrespective of the presence or absence of driver mutations. Conclusions Our findings suggest that aberrant gene expression linked to structural polymorphisms can significantly impact personalized cancer treatment by facilitating the identification of driver mutations and prognostic factors, contributing to a more comprehensive understanding of LUAD pathogenesis.
Exome sequence analysis identifies rare coding variants associated with a machine learning-based marker for coronary artery disease
Authors: Ben Omega Petrazzini, Iain S. Forrest, Ghislain Rocheleau, Ha My T. Vy, Carla Márquez-Luna, Áine Duffy, Robert Chen, Joshua K. Park, Kyle Gibson, Sascha N. Goonewardena, Waqas A. Malick, Robert S. Rosenson, Daniel M. Jordan, Ron Do
Journal: Nature Genetics (2024)
Decision uncertainty as a context for motor memory
Authors: Kisho Ogasa, Atsushi Yokoi, Gouki Okazawa, Morimichi Nishigaki, Masaya Hirashima, Nobuhiro Hagura
Journal: Nature Human Behaviour (2024)

The current view of perceptual decision-making suggests that once a decision is made, only a single motor programme associated with the decision is carried out, irrespective of the uncertainty involved in decision making. In contrast, we show that multiple motor programmes can be acquired on the basis of the preceding uncertainty of the decision, indicating that decision uncertainty functions as a contextual cue for motor memory. The actions learned after making certain (uncertain) decisions are only partially transferred to uncertain (certain) decisions. Participants were able to form distinct motor memories for the same movement on the basis of the preceding decision uncertainty. Crucially, this contextual effect generalizes to novel stimuli with matched uncertainty levels, demonstrating that decision uncertainty is itself a contextual cue. These findings broaden the understanding of contextual inference in motor memory, emphasizing that it extends beyond direct motor control cues to encompass the decision-making process.
Body mass index stratification optimizes polygenic prediction of type 2 diabetes in cross-biobank analyses
Authors: Takafumi Ojima, Shinichi Namba, Ken Suzuki, Kenichi Yamamoto, Kyuto Sonehara, Akira Narita, Yoichiro Kamatani, Gen Tamiya, Masayuki Yamamoto, Toshimasa Yamauchi, Takashi Kadowaki, Yukinori Okada
Journal: Nature Genetics (2024)